Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What Does Roche Holding Ltd. (ADR) (RHHBY)’s Inovio Pharmaceuticals Inc (INO) Deal Mean for Investors?

Page 1 of 2

Especially in the health care sector, a company’s technology can matter much more than most other aspects of its business. Inovio Pharmaceuticals Inc (NYSEMKT:INO) is a case in point. For the last two months or longer, some have questioned the stock, while many longs have looked for a windfall without focusing on what Inovio Pharmaceuticals Inc (NYSEMKT:INO) is all about from a purely health care perspective.

Inovio Pharmaceuticals Inc (NYSEAMEX:INO)

Then yesterday, Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) went ahead and signed a deal that added a new twist to the story.

In the deal, Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) has agreed to pay $10 million up front and milestones of more than $400 million plus double-digit royalties for two of Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s vaccines and the technology used to administer them. These vaccines, one for prostate cancer and the other for hepatitis B, are still in pre-clinical development, but shares are up since the start of the month. Therefore, it is very important for investors to really figure out what health care research Inovio Pharmaceuticals Inc (NYSEMKT:INO) is doing.

What cancer immunotherapy is all about
The human immune system has a natural ability to fight foreign bodies. The so-called white knights doing most of the fighting at a cellular level are white blood cells known as T-cells. Cancerous cells manage to dupe these T-cells into “thinking” that they are not the enemy. So, the natural killing abilities of T-cells are suppressed, letting cancer cells grow and destroy the body.

Chemotherapy is an external means of killing cancer cells. It is not an intelligent method — it kills indiscriminately. Recent research has therefore focused on developing the body’s own immune system to fight against cancer, mostly by enhancing, activating, and increasing the number of T-cells in the body.

Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s prostate cancer pipeline product INO-5150 has been shown to markedly improve T-cell response in animal studies, and it is expected that once it gets into clinical trial, similar robust T-cell response should be found in human studies as well. This is very, very important for the future of cancer research, which is where Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY)’s interest is coming from.

The hepatitis-B vaccine
The hepatitis-B virus, or HBV, apart from causing potentially life threatening hepatitis B infection, also attacks the liver and may also progress into cirrhosis of the liver and liver cancer. There is no specific treatment, and HBV vaccine that produces protective antibody levels is the mainstay of prevention. INO-1800, Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s candidate for a hepatitis-B vaccine, demonstrated that it not only produces antibody responses but could also kill targeted liver cells in mice by inducing strong T-cell response.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!